Journal: Social Studies of Science

Article Title: Groundwork for AI: Enforcing a benchmark for neoantigen prediction in personalized cancer immunotherapy

doi: 10.1177/03063127231192857

Figure Lengend Snippet: Schematic of a putative neoantigen. The mass on the far left of the figure represents a solid cancer cell. The two growths emanating from it—named MHC I—refer to the major histocompatibility complex, a molecular arrangement whose many functions include displaying peptides derived from turnover proteins on the surface of the cancer cell. The mass on the far right of the figure represents a T-cell. The two outgrowths emanating from it, named TCR (symmetric to MHC I), refer to the T-cell receptor. In the center of the figure lies the putative neoantigen, a peptide that carries great hopes for personalized cancer immunotherapy. Source : Reproduced with permission from .

Article Snippet: In May 2020, BioNTech acquired the start-up Neon—active in the field of neoantigen-specific adoptive cell therapy—for $97 million.

Techniques: Derivative Assay

Journal: Bone Marrow Transplantation

Article Title: The 46 th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Poster Session (P001-P706)

doi: 10.1038/s41409-020-01120-w

Figure Lengend Snippet:

Article Snippet: Chiara Bonini received research founding by Intellia Therapeutics, is owner of patents in the field of adoptive T-cell therapy and is a consultant of Molmed Spa, Intellia therapeutics, TxCell, Novartis, GSK, Allogene and Kite/Gilead.

Techniques: